Parenteral nutrition

Soleo Health Unveils Pharmacy in Jackson, MS; Marks Pharmacy Entry Into State

Retrieved on: 
Monday, April 29, 2024
Professional Services, Other Science, Research, Science, Practice Management, Nursing, Medical Supplies, Other Health, Managed Care, FDA, General Health, Diabetes, Radiology, Pharmaceutical, Oncology, Medical Devices, Infectious Diseases, Hospitals, Software, Genetics, Fitness & Nutrition, Clinical Trials, Cardiology, Biotechnology, AIDS, Technology, Health, Surgery, Insurance, Ulcerative colitis, Pharmacy, Crohn's disease, Immunodeficiency, Graves' ophthalmopathy, AIC, Alzheimer's disease, Parenteral nutrition, Patient, ALS, Rheumatoid arthritis, Hattiesburg, Mississippi, Medical device

Soleo Health , a national provider of complex specialty pharmacy services, announced today the opening of its latest pharmacy and ambulatory infusion center (AIC) in Ridgeland, Mississippi.

Key Points: 
  • Soleo Health , a national provider of complex specialty pharmacy services, announced today the opening of its latest pharmacy and ambulatory infusion center (AIC) in Ridgeland, Mississippi.
  • The new Soleo Health Jackson location, at 1250 E. County Line Road, Ridgeland, Mississippi, 601.427.4510, is a state-of-the-art pharmacy supporting patients in their homes or at its ambulatory infusion center.
  • Soleo Health Jackson specializes in providing biologic and infusion therapies for patients with complex, rare and ultra-rare diseases and autoimmune disorders.
  • “Soleo Health identified an opportunity to expand its reach in Mississippi by bringing its complex specialty pharmacy services to the marketplace.

$1.25 Billion Parenteral Nutrition Bags Markets by Chamber Type, Consumer, End User - Global Forecast to 2031 - ResearchAndMarkets.com

Retrieved on: 
Friday, April 19, 2024
Seniors, Pharmaceutical, Health, Parenting, Children, Baby, Maternity, Consumer, Fitness & Nutrition, Irritable bowel syndrome, Dicarboxylic acid, DSM-IV codes, Risk, Hospital, Route of administration, Indigestion, Parenteral nutrition, Prevalence, Rome process, Vitamin, Electrolyte, Incidence, Patient, Developed country, Carbohydrate, Malnutrition, Pharmacy, Element, Lipid, Growth, Infection, Pet industry

The "Parenteral Nutrition Bags Market by Chamber Type (Single-Chamber Bags, Dual-Chamber Bags, Multi-Chambered Bags), Consumer (Adults, Children), End User (Healthcare Facilities, Pharmacies & Compounding Service Providers) - Global Forecast to 2031" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Parenteral Nutrition Bags Market by Chamber Type (Single-Chamber Bags, Dual-Chamber Bags, Multi-Chambered Bags), Consumer (Adults, Children), End User (Healthcare Facilities, Pharmacies & Compounding Service Providers) - Global Forecast to 2031" report has been added to ResearchAndMarkets.com's offering.
  • The global parenteral nutrition bags market is projected to reach $1.25 billion by 2031, at a CAGR of 6.6% from 2024 to 2031.
  • The lack of awareness regarding parenteral nutrition in developing countries is a major challenge impacting the growth of the parenteral nutrition bags market.
  • Among chamber types, in 2024, the single-chamber parenteral nutrition bags segment is expected to account for the largest share of the parenteral nutrition bags market.

Protara Therapeutics Announces Alignment with FDA on Registrational Path Forward for IV Choline Chloride in Patients Dependent on Parenteral Nutrition

Retrieved on: 
Friday, April 5, 2024
Choline, Plasma, Liver, Nutritional science, Route of administration, Liver disease, Steatosis, Short bowel syndrome, Metabolism, Patient, Choline chloride, Cancer, ESPEN, Parenteral nutrition, Adolescence, Liver injury, Hepatology, Tubing (recreation), Fibrosis, Guideline, Society, Therapy, Copenhagen University Hospital, Safety, Pharmacokinetics, PN, FDA, ASPEN, Rigshospitalet, Food, Feeding tube, Extractive metallurgy

IV Choline Chloride has the potential to become the first FDA-approved IV formulation of choline for the 40,000 PN patients in the U.S.

Key Points: 
  • IV Choline Chloride has the potential to become the first FDA-approved IV formulation of choline for the 40,000 PN patients in the U.S.
  • The Company plans to advance the development of IV Choline Chloride as a source of choline for adult and adolescent patients on long-term PN.
  • The FDA has granted IV Choline Chloride Orphan Drug Designation for the prevention of choline deficiency in PN patients.
  • “We look forward to advancing the clinical development of IV Choline Chloride, which we believe has the potential to become the first FDA approved IV choline therapy for patients dependent on PN.

Orphan designation: Alisitol, retinol palmitate, zinc gluconate Treatment of microvillus inclusion disease, 13/11/2020 Positive

Retrieved on: 
Tuesday, April 9, 2024
Eurostat, Civil service commission, Salt, Diagnosis, Absorption, Microvillous inclusion disease, DSM-IV codes, Nutrient, Cell, Patient, Committee, Weight loss, Knowledge, Regulation, Food, EMA, IRIS, Noetics, Parenteral nutrition, Diarrhea, European, Malnutrition, COMP, Dehydration, Water, Safety, European Commission, Liver, Medicine, Pharmaceutical industry

Orphan designation: Alisitol, retinol palmitate, zinc gluconate Treatment of microvillus inclusion disease, 13/11/2020 Positive

Key Points: 


Orphan designation: Alisitol, retinol palmitate, zinc gluconate Treatment of microvillus inclusion disease, 13/11/2020 Positive

Global Enteral Feeding Devices Market Insights 2024-2029 with Avanos Medical and B. Braun Melsungen Leading through Substantial R&D Investments - ResearchAndMarkets.com

Retrieved on: 
Tuesday, March 12, 2024
Health, Medical Devices, Other Health, Hospital, Cardiology, Incidence, Enterostomy, Neurology, Conditional sentence, Growth, Prevalence, Obesity, Esophagitis, DSM-IV codes, Patient, Research, GI, Cancer, HEN, Crohn's disease, Ageing, Parenteral nutrition, Syringe, Diet, Gastrointestinal disease, Investment, Malnutrition, Safety, IBS, Dysphagia, USD, Avanos Medical, Tubing (recreation), Pediatrics, PEG

The enteral feeding devices market features diverse players, from well-established giants to dynamic emerging entities, focusing on innovation and strategic growth.

Key Points: 
  • The enteral feeding devices market features diverse players, from well-established giants to dynamic emerging entities, focusing on innovation and strategic growth.
  • Leading firms such as Avanos Medical and B. Braun Melsungen distinguish themselves through substantial research and development (R&D) investments, forming strategic alliances, and initiatives to increase their market share.
  • The enteral feeding devices market is set for sustained growth, driven by healthcare advancements and a global emphasis on chronic disease management and nutritional support.
  • North America, particularly the United States and Canada, leads in the enteral feeding devices market.

Rising Aging Population and Changing Healthcare Preferences Fuel Home Infusion Therapy Market Growth - ResearchAndMarkets.com

Retrieved on: 
Monday, November 6, 2023
Health, Other Health, Ageing, Fungal infection, Medicine, Prevalence, Endocrinology, Diabetes, Intake, Infusion pump, Quality of life, Parenteral nutrition, Cystic fibrosis, DSM-IV codes, Hospital, Patient, Patient safety, Vels Institute of Science, Technology & Advanced Studies, Cardiovascular disease, Pharmaceutical industry, Medical device, Growth

Home infusion therapy involves the intravenous or non-oral delivery of medication, offering convenience and 24/7 monitoring by healthcare professionals.

Key Points: 
  • Home infusion therapy involves the intravenous or non-oral delivery of medication, offering convenience and 24/7 monitoring by healthcare professionals.
  • Product: Infusion pumps dominate the home infusion therapy market due to their crucial role in ensuring accurate medication dosing and continuous monitoring.
  • The United States leads the home infusion therapy market, driven by an aging population with complex healthcare needs and a preference for home-based treatment options.
  • The U.S. market is positioned for ongoing growth due to a supportive regulatory environment and increasing awareness of the benefits of home infusion therapy.

CalciMedica Announces Presentation of Initial Data from the CRSPA Study of Auxora at the 65th Annual ASH Meeting & Exposition

Retrieved on: 
Thursday, November 2, 2023
Acute lymphoblastic leukemia, CRAC, T16, Asparaginase, LA, Society, Severity, ASH, Pancreatitis, TPN, AAP, St. Jude Children's Research Hospital, Patient, ALL, Parenteral nutrition, ICU, Pharmaceutical industry

LA JOLLA, Calif., Nov. 2, 2023 /PRNewswire/ -- CalciMedica Inc. ("CalciMedica") (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic diseases, today announced that there will be a presentation of data from the initial cohort of the CRSPA study of Auxora™ (zegocractin) in asparaginase-induced pancreatic toxicity (AIPT) in a poster presentation at the 65th Annual American Society of Hematology (ASH) Meeting & Exposition being held December 9-12, 2023 in San Diego, CA.

Key Points: 
  • The presentation includes results from the first cohort consisting of nine patients from the CRSPA study.
  • ONCASPAR™ and RYLAYZE™), a nearly identical ALL treatment protocol as used in the CRSPA study.
  • Additionally, no CRSPA patients required total parenteral nutrition (TPN), compared to 68.8% in the historical matched control group.
  • Presentation Title: Zegocractin to Reduce the Severity of Asparaginase Associated Pancreatitis in Children with Acute Lymphoblastic Leukemia: Results of the Phase 1 Portion of the CRSPA Study

American Regent Introduces Potassium Phosphates, USP; FDA-Approved and "AP" Rated¹

Retrieved on: 
Thursday, October 19, 2023
Cardiac arrest, ECG, Injection, Seizure, Arrhythmia, Nephrocalcinosis, Hypercalcaemia, Infant, Kidney, Continuity, Risk, Hyperkalemia, Death, Parenteral nutrition, Child, Potassium, Lactation, Thrombosis, Acute kidney injury, Milk, Tetany, Toxicity, Phosphate, Patient, Central nervous system, Bolus, Hyperphosphatemia, Hypophosphatemia, Hypotension, Hypocalcemia, Tubing (recreation), Pulmonary embolism, Use, Aluminium, Administration, Late preterm infant, QT, Calcium, Ketoacidosis, Phosphorus, Birth control, Medical device, Pharmaceutical industry, Magnesium deficiency

In addition, inappropriate intravenous administration of undiluted or insufficiently diluted potassium phosphates as a rapid "IV push" has resulted in cardiac arrest, cardiac arrhythmias, hypotension, and death.

Key Points: 
  • In addition, inappropriate intravenous administration of undiluted or insufficiently diluted potassium phosphates as a rapid "IV push" has resulted in cardiac arrest, cardiac arrhythmias, hypotension, and death.
  • Vein Damage and Thrombosis: Potassium Phosphates Injection must be diluted and administered in intravenous fluids or used as an admixture in parenteral nutrition.
  • You are encouraged to report adverse drug events to American Regent, Inc. at 1-800-734-9236 or to the FDA by visiting www.fda.gov/medwatch or calling 1-800-FDA-1088.
  • You are encouraged to report adverse drug events (ADEs) to American Regent:
    ADEs may also be reported to the FDA:

NorthSea Therapeutics Receives FDA Rare Pediatric Disease Designation for SEFA-6179 for the Treatment of Intestinal Failure-Associated Liver Disease

Retrieved on: 
Tuesday, October 17, 2023
Biotechnology, FDA, Health, Pharmaceutical, Clinical Trials, Pediatrics, Hope, PRV, SEFA, PK, Priority review, Pharmacotherapy, Hospital, Nutritional science, RPD, Fatty liver disease, NASH, Gastrointestinal tract, NST, NDA, Parent, PD, DSM-IV codes, Parenteral nutrition, TPN, Short bowel syndrome, Portsmouth Northsea Swimming Club, Patient, Pharmaceutical industry, Nursing, Drug discovery

SEFA-6179 is a novel, oral, fully synthetic medium chain fatty acid analog for the treatment of IFALD.

Key Points: 
  • SEFA-6179 is a novel, oral, fully synthetic medium chain fatty acid analog for the treatment of IFALD.
  • IFALD, also known as Parental Nutrition-Associated Liver Disease (PNALD), is an orphan liver disease which is a frequent consequence of total parenteral nutrition, or TPN, a life-saving therapy for individuals with intestinal failure caused by insufficient bowel-length or function.
  • The granting of RPD designation for SEFA-6179 underscores the critical need for novel therapies to address IFALD in the pediatric population.
  • This program is intended to encourage the development of new drugs and biologics for the treatment of rare pediatric diseases.

Ironwood Pharmaceuticals Presents Positive Final Data from STARS Nutrition, a Phase II Study of Apraglutide in Short Bowel Syndrome with Intestinal Failure (SBS-IF) and Colon in Continuity (CIC) at United European Gastroenterology Week

Retrieved on: 
Monday, October 16, 2023
Health, FDA, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Short bowel syndrome, Pharmacokinetics, United European Gastroenterology, Weaning, Risk, Trial of the century, Safety, Survival, Bronchoscopic lung volume reduction, Colon, SBS, Growth, PS, Gambat Liver Transplant Center, Ironwood Pharmaceuticals, Patient, UEG, Infection, Medication, CIC, Parenteral nutrition, STARS, Nutrition, Quality of life, Pharmaceutical industry, Birth control, Ironwood, Basel

Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a global GI-focused healthcare company, presented positive final data from the company’s Phase II STARS Nutrition program during United European Gastroenterology (UEG) Week.

Key Points: 
  • Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a global GI-focused healthcare company, presented positive final data from the company’s Phase II STARS Nutrition program during United European Gastroenterology (UEG) Week.
  • PS reduction was observed as early as week four and was maintained until the end of the study.
  • Seventy-eight percent (78%) of patients gained one or more days off PS with all patients achieving clinical response.
  • “We welcome these results and are continuing to progress the apraglutide development in the SBS-IF program with a sense of urgency.”